MedAI Verdict
Radiology

AI Radiology

Brainomix logo

Brainomix

by Brainomix Limited  ·  founded 2012  ·  GB

Last verified

FDA-cleared AI scoring and large vessel occlusion flagging for stroke CT, CTA, CTP and MRI, plus CT lung quantification.

Visit Brainomix (opens in new tab)Read our methodology

At a glance

Pricing
No public price.
HIPAA
Not disclosed
SOC 2
Not disclosed
EHRs
—
Founded
2012
HQ
GB
On this page

Independent score  ·  By our public rubric

64/100Top-ranked

Editorial rating 4.5 / 5

How it’s computed →
  • Regulatory & Compliance
    18/28

    FDA cleared (13 K-numbers on record)

  • Clinical Integration
    0/6.6

    No EHR integrations listed

  • Evidence Strength
    18.2/26

    5 peer-reviewed papers

  • Vendor & Market
    14.4/18

    Mid-tier funding and adoption

  • Sentiment & Transparency
    2.5/5

    Pricing on request, no public amounts

▸ Show all 11 dimensions

Regulatory & Compliance

  • FDA clearance18/18

    FDA cleared (13 K-numbers on record)

  • HIPAA / SOC2 / BAA0/10

    No public HIPAA/SOC2/BAA attestation

Clinical Integration

  • EHR integrations (count)0/4

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0/2

    None of the top-3 EHRs covered

Evidence Strength

  • Peer-reviewed papers18/18

    5 peer-reviewed papers

  • RCT / meta-analysis / systematic review0/8

    No RCT, meta-analysis, or systematic review

Vendor & Market

  • Funding & adoption signal8/12

    Mid-tier funding and adoption

  • Years in market6/6

    Founded 2012 (14 years)

Sentiment & Transparency

  • Pricing transparency3/5

    Pricing on request, no public amounts

Scored November 2, 2026 · Public scoring method v1.2.0

FDA-cleared AI scoring and large vessel occlusion flagging for stroke CT, CTA, CTP and MRI, plus CT lung quantification.

No public price.

Evidence record

FDA decisions
Show 8 more
Peer-reviewed

5 studies on PubMed: 5 other, published 2025 to 2026. Read the literature summary

Verification
  • Score computed November 2, 2026, method 1.2.0
  • Review written November 2, 2026
Cite this record

MedAI Verdict, Brainomix record, https://medaiverdict.com/tools/brainomix, version November 2, 2026

Change history
View every change to this record

Bottom line

Brainomix Limited, an Oxford company founded in 2012 as a University of Oxford spinout, sells the Brainomix 360 platform, and FDA's records list thirteen 510(k)s under its name. The stroke modules cover non-contrast CT, CT angiography, CT perfusion and MRI, and a lung module quantifies fibrosis-type disease on chest CT. It fits a hospital that wants stroke imaging analysis and triage notification from one vendor. The security claims on the vendor's pages are ISO 27001 certification and GDPR compliance. The vendor sells through demo requests with no public price.

What does Brainomix 360 contain?

Brainomix 360 is the platform name, and the vendor's modules are e-Stroke, e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage, e-Lung and Vantage. The vendor describes ASPECTS scoring on non-contrast CT, smartphone alerts for suspected large vessel occlusion and intracranial hemorrhage, LVO detection and a collateral score on CT angiography, perfusion mismatch measures, DWI-FLAIR mismatch on MRI and a network analytics dashboard in Vantage. According to the vendor, results return to PACS as annotated DICOM series or PDF reports, sign-on supports LDAP, Microsoft AD and SSO with MFA, and deployment runs on a dedicated server, a virtual server or a secure cloud environment.

What has FDA cleared?

The thirteen records run from K192692 (Brainomix 360 e-CTA, May 28, 2020) to K260406 (Brainomix 360 Hyperdensity, June 12, 2026). The vendor counts "35+" regulatory clearances worldwide. Three Triage modules, for ICH, LVO and stroke, carry the QAS product code and are notification tools, and Triage Stroke was cleared as K232496 on November 21, 2023. e-ASPECTS, e-CTA and e-Lung each have two clearances, and e-CTP and e-MRI have one each.

What do the studies measure?

PMID 38164621 is a real-world evaluation of e-Stroke on 1,130 scans, 97.2% of which were processed in about four minutes, with accuracy reported for MCA findings. PMID 36053916 is an external validation of e-ASPECTS for CT ischemia and hemorrhage. A 2020 comparison of three ASPECTS tools in 131 patients included e-ASPECTS, RAPID ASPECTS and Syngo.via Frontier, and a 2026 scoping review covers Brainomix, Aidoc, RapidAI and Viz.ai together.

What does Brainomix claim about scale and outcomes?

The vendor reports 3.5M+ scans, 80+ publications, deployment in 20+ countries, £49M raised in private investment and public funding, and "60+ peer-reviewed studies involving over 450,000 patients". It cites Nagaratnam and colleagues (Lancet Digital Health, 2025) for a 100% increase in thrombectomy rates across 107 hospitals and 452,000 patients over five years. The vendor points to the NHS England rollout and publishes no price.

The verdict

Brainomix fits a hospital with CT and MRI stroke pathways that wants ASPECTS scoring, LVO flags and perfusion analysis from one platform, and the three QAS modules are notification tools.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

What it costs

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price.

Source: vendor pricing page. Last checked November 2, 2026.

What deploys cleanly

Carries FDA 510(k), CE, ISO 27001 per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Who builds it

Brainomix (Brainomix Limited) was founded in 2012 in GB, putting it 14 years into market.

What the literature says

5 peer-reviewed studies indexed on PubMed evaluate Brainomix in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.

Transforming Stroke Diagnosis with Artificial Intelligence: A Scoping Review of Brainomix e-Stroke, Aidoc, RapidAI, and Viz.ai. (opens in new tab)
Dorochowicz M, Kacała A, Tołkacz A, et al.· Medicina (Kaunas)· 2026
: Rapid diagnosis is fundamental to acute ischemic stroke management; however, access to neuroradiological expertise remains limited. This scoping review maps the diagnostic accuracy, workflow impact, and cost-effectiveness of leading AI platforms (Brainomix, Aidoc, RapidAI, and Viz.ai), characterizing industry and peer-reviewed metrics.: Following PRISMA-ScR guidelines, we searched PubMed, Cochrane Library, and HTA repositories for studies (2019-2025). Using a PICO-based framework, 29 studies were included for thematic mapping of the technological landscape.: Twenty-nine studies were include…
Real world clinical experience of using Brainomix e-CTA software in a medium size acute National Health Service Trust. (opens in new tab)
Merchant F, Choulerton J, James R, et al.· Br J Radiol· 2025
Artificial intelligence (AI) software including Brainomix "e-CTA" which detect large vessel occlusions (LVO) have clinical potential. We hypothesized that in real world use where prevalence is low, its clinical utility may be overstated. In this single centre retrospective service evaluation project, data sent to Brainomix from a medium size acute National Health Service (NHS) Trust hospital between January 3, 2022 and January 3, 2023 was reviewed. 584 intracranial computed tomography angiogram (CTA) datasets were analysed for LVO by e-CTA. The e-CTA output and radiology report were compared…
Assessing the eligibility of Brainomix e-ASPECTS for acute stroke imaging. (opens in new tab)
Dorochowicz M, Kacała A, Puła M, et al.· Front Neuroinform· 2025
Timely and accurate assessment of acute ischemic stroke is crucial for determining eligibility for mechanical thrombectomy. The Alberta Stroke Program Early CT Score (ASPECTS) is a widely used tool for evaluating early ischemic changes on non-contrast CT (NCCT), but its interpretation is subject to interobserver variability. Brainomix e-ASPECTS is an automated software designed to standardize and expedite this assessment. We aimed to evaluate the clinical utility and diagnostic performance of the Brainomix e-ASPECTS software in an unselected, real-world cohort of patients undergoing NCCT for…
Evaluation of Lung Volume Reduction in Patients with Interstitial Lung Disease Using Brainomix e-Lung. (opens in new tab)
Sabashnikov A, Agrawal S, Zych B, et al.· J Clin Med· 2026
e-Lung (Brainomix) is an artificial intelligence (AI)-driven software that is based on multi-class convolutional neural network (CNN) techniques. The aim of this research was to demonstrate the feasibility of e-Lung to evaluate progression in lung volume reduction in patients with interstitial lung disease (ILD) undergoing lung transplant assessments.This was a single-center retrospective cohort study of consecutive patients with ILD who received lung transplants between June 2021 and November 2024. Patients who underwent serial prospective conventional evaluations using lung function testing…
One scan, two answers: RAPID vs Brainomix agreement in thrombectomy patients. (opens in new tab)
McHugh P, Boylan E, Looby S, et al.· J Neurointerv Surg· 2026
Automated CT perfusion (CTP) software is widely used to select patients with large-vessel occlusion stroke for endovascular thrombectomy (EVT), yet treatment thresholds are often applied as if outputs from different platforms are interchangeable. This study compared RAPID and Brainomix CTP outputs in the same thrombectomy cohort. We performed a retrospective observational study of patients with large vessel occlusion who underwent CTP imaging. Paired volumetric data were analyzed using both RAPID and Brainomix algorithms. Inter-platform agreement was assessed using intraclass correlation coef…

See all on PubMed (opens in new tab)

Other radiology

See the full radiology ranking